Lupin Share Price (LUPIN)
as on 01 Aug 2025, 04:01 PM IST
| Source : NSE
Lupin Stock Performance
as on 01 Aug 2025, 04:01 PM IST
Day's Low
Day's High
₹1,860.7₹1,931
0.35%
Downside
3.41%
Upside
52 Week's Low
52 Week's High
₹1,795.2₹2,402.93.86%
Downside
28.68%
Upside
| Market Stats | |
| Previous Close | ₹1,929.10 |
| Open | ₹1,931.00 |
| Volume | 12.43L |
| Upper Circuit | ₹2,122.00 |
| Lower Circuit | ₹1,736.20 |
| Day's Low | ₹1,860.7 |
| Day's High | ₹1,931 |
| 52 Week Low | ₹1,795.2 |
| 52 Week High | ₹2,402.9 |
| Returns % | |
| 1 Month Return | -5.14 % |
| 3 Month Return | -9.23 % |
| 1 Year Return | -4.8 % |
| 3 Year Return | + 192.38 % |
| 5 Year Return | + 101.29 % |
Lupin Stock Fundamentals & Key Indicators
Check Lupin market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹85,288.43 Cr
Return on Equity (ROE)
17.7
PE Ratio (TTM)
25.95
Return on capital employed (ROCE)
21.32
Industry PE ratio
44.86
Beta (LTM)
0.79
P/B Ratio
3.81
Dividend Yield
0.59
PEG Ratio
0.87
Quarterly Earnings Growth YOY
112.48
EPS (TTM)
72.41
Sector
Pharmaceuticals
Book Value
376.77
Technical Analysis
Bearish
View Technical Analysis
Lupin Stock's Interest Amongst Investors
Lupin Stock Valuation
Track how Lupin P/E has moved over time to understand its valuation trends.
Lupin in the last 5 years
Lowest (-6437.86x)
December 3, 2018
Today (25.95x)
August 1, 2025
Industry (44.86x)
August 1, 2025
Highest (517.33x)
December 2, 2022
Today’s Price to Earnings Ratio: 25.95x
Lupin Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Lupin.
based on 37 analysts
54.05%
Buy
35.14%
Hold
10.81%
Sell
54.05% of analysts recommend a 'BUY' rating for Lupin. Average target price of ₹2230.43
Source: S&P Global Market Intelligence
Lupin Share Price Target
Get share price movements and forecasts by analysts on Lupin.
Lupin price forecast by 37 analysts
Upside of19.45%
High
₹2626
Target
₹2230.43
Low
₹1731
Lupin target price ₹2230.43, a slight upside of 19.45% compared to current price of ₹1867.3. According to 37 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Lupin revenue growth forecast
Expected growth rate Q1, FY2027:17.76%
Forecast
Actual
Including amortisation and stock based compensations
Lupin EPS growth forecast
EPS estimate Q1, FY2027:23.46%
Forecast
Actual
Source: S&P Global Market Intelligence
Lupin Ltd Financial Results
Get the annual and quarterly financial summary of Lupin Ltd, including revenue, profit, loss and more.
Lupin Earnings and Dividends
View detailed summary of the earnings and dividend history of Lupin.
Lupin Ltd Earnings Results
Lupin Ltd’s net profit jumped 114.93% since last year same period to ₹772.52Cr in the Q4 2024-2025. On a quarterly growth basis, Lupin Ltd has generated -9.66% fall in its net profits since last 3-months.
Read More about Earnings ResultsLupin Ltd Dividends May,2025
In the quarter ending March 2025, Lupin Ltd has declared dividend of ₹12.00 per share on 14 May 2025 - translating a dividend yield of 0.64%.
Read More about Dividends
Indices Featuring Lupin Stock
Check stock indices that include Lupin.
Lupin Stock Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Lupin.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 46.9% | ||
| Foreign Institutions | 21.25% | ||
| Mutual Funds | 19.35% | 10.29 | |
| Retail Investors | 6.28% | 1.22 | |
| Others | 6.21% |
Lupin Ltd vs Peers
Compare market cap, revenue, PE, and other key metrics of Lupin with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 85,288.43 | 20.26% | 0.52 | 3,306 | 22,707 | |
| BUY | 12,781.65 | -6.62% | 0.52 | 413 | 2,013 | |
| BUY | 63,269.65 | 4.91% | 0.56 | 3,168 | 29,001 | |
| HOLD | 95,496.64 | 28.1% | 0.64 | 4,614 | 23,241 | |
| BUY | 71,389.38 | 21.97% | 0.53 | NA | NA |
Lupin News & Key Events
Latest news and events in one place to help you make informed investing decisions in Lupin.
Lupin Initiates Recall of Blood Pressure Medication - 27 Jul, 2025
Lupin Pharmaceuticals is recalling 58,968 bottles of Lisinopril and Hydrochlorothiazide tablets due to a product mix-up. The recall, classified as Class II, affects a lot manufactured at their Nagpur facility.Lupin Receives GMP Certification Amid FDA Observations - 18 Jul, 2025
Lupin's Dabhasa facility achieved GMP certification from TGA, while its Pithampur Units 2 and 3 received Form-483s from USFDA, noting several observations. The company is addressing these issues promptly.Lupin Launches Generic Eye Medication in U.S. - 16 Jul, 2025
Lupin has launched Loteprednol Etabonate Ophthalmic Suspension, a generic equivalent to Lotemax, in the U.S. market, targeting eye inflammation and pain. The product had estimated annual sales of USD 55 million. This launch enhances Lupin's ophthalmic portfolio and commitment to affordable treatments.Morgan Stanley Rates Lupin with Equal-weight - 14 Jul, 2025
Morgan Stanley has initiated coverage on Lupin with an Equal-weight rating and a target price of ₹2,096, anticipating a strong first half of FY26 but highlighting risks from U.S. competition in key products.Lupin Partners with Zentiva for Biosimilar Expansion - 09 Jul, 2025
Lupin has entered a strategic licensing and supply agreement with Zentiva for its biosimilar Certolizumab Pegol, enhancing global market reach and sharing profits. The deal includes an upfront payment of $10 million and potential milestone payments of up to $50 million.Lupin Launches Ipratropium Bromide Nasal Spray in US - 04 Jul, 2025
Lupin has launched Ipratropium Bromide nasal spray in the US, a generic version of Atrovent, aiming to increase complex generics revenue share to 62% by FY30.Lupin Launches Subsidiary for Consumer Healthcare - 03 Jul, 2025
Lupin Ltd has launched a wholly owned subsidiary focused on consumer healthcare, aiming to enhance its presence in India's growing self-care and OTC healthcare markets.Lupin Announces Strategic Moves and FDA Approval - 01 Jul, 2025
Lupin has carved out its consumer healthcare business into a subsidiary, LupinLife Consumer Healthcare, effective July 1, 2025. The stock rose 1.56% following this announcement. Additionally, Lupin received FDA approval for Loteprednol Etabonate Ophthalmic Gel, securing 180 days of exclusivity.Lupin Transfers OTC Business to Subsidiary - 30 Jun, 2025
Lupin has executed a Business Transfer Agreement to transfer its Over-the-Counter Consumer Healthcare Business to its wholly owned subsidiary, LUPINLIFE Consumer Healthcare, effective July 1, 2025.Lupin Prepares US Strategy for Etanercept Patent Expiry - 29 Jun, 2025
Lupin Ltd is strategizing for the US commercialization of its autoimmune biologic Etanercept, aiming to finalize plans before the drug's patent expires in 2029.
Insights on Lupin Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRetail Holding Up
Retail Investor have increased holdings from 6.20% to 6.28% in Jun 2025 quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, LUPIN has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 17.55% to 19.35% in Jun 2025 quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 27.5% return, outperforming this stock by 32.3%
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 21.46% to 21.25% in Jun 2025 quarter
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 46.92% to 46.90% in Jun 2025 quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 5.82K Cr → 5.72K Cr (in ₹), with an average decrease of 1.7% per quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 855.16 Cr → 772.52 Cr (in ₹), with an average decrease of 9.7% per quarter
- NEGATIVE IMPACT
Price Dip
In the last 7 days, LUPIN stock has moved down by -4.8%
About Lupin Ltd
The company's top products include a wide range of prescription and over-the-counter drugs, including antibiotics, cardiovascular medications, antidiabetics, and anti-asthmatics. Lupin Ltd also manufactures and markets a variety of branded products, including Metoject, Lupitac, and Lupizole. In addition, the company produces a number of popular generic drugs, such as Amlodipine, Montelukast, and Cetirizine.
Lupin Ltd is one of the world's leading manufacturers of APIs, with a portfolio that includes more than 200 APIs and intermediates. The company also produces a range of animal health products, such as veterinary vaccines, feed supplements, and pet care products.
Revenue: ₹5,562.20Cr as on March 2025 (Q4 FY25)
Net Profit: ₹782.38Cr as on March 2025 (Q4 FY25)
Listing date: 30 Nov, 1994
Chairperson Name: M D Gupta
| Organisation | Lupin Ltd |
| Industry | Pharmaceuticals |
| CEO | M D Gupta |
| E-voting on shares | Click here to vote |
Mutual Funds that own Lupin Stock
Check out the Mutual Funds with significant holdings in Lupin.
FAQs
What is Lupin share price today?
Lupin share price today stands at ₹1867.3, Open: ₹1931, Previous Close: ₹1929.1, High: ₹1931, Low: ₹1860.7, 52 Week High: ₹2402.9, 52 Week Low: ₹1795.2 as on 01 Aug 2025, 04:01 PM IST.
How to buy Lupin shares ?
To buy Lupin shares, you need to follow these steps:
- Open a Demat account and Trading account on INDmoney
- Fund your Trading account
- Search for LUPIN or Lupin Ltd on the INDmoney app to check live prices of the stock
- Click on Buy or SIP to place an order to invest in Lupin shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
What is today's traded volume of Lupin?
Today's traded volume of Lupin is 12.43L. Which means that 12.43L shares of Lupin were bought and sold on the stock market during today's trading session.
What is Lupin's market cap today?
Today's market capitalisation of Lupin is ₹85,288.43 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Lupin?
Lupin’s 52 week high is ₹2402.9 and 52 week low is ₹1795.2. The current share price of Lupin is ₹1867.3, which is -22.29% down from its 52 week high and 4.02% up from its 52 week low.